Cargando…

Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer

Breast cancer (BC) is the most common malignancy among women worldwide. In recent years, significant progress has been made in BC therapy. However, serious side effects resulting from the use of standard chemotherapeutic drugs, as well as the phenomenon of multidrug resistance (MDR), limit the effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Okon, Estera, Gaweł-Bęben, Katarzyna, Jarzab, Agata, Koch, Wojciech, Kukula-Koch, Wirginia, Wawruszak, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648492/
https://www.ncbi.nlm.nih.gov/pubmed/37958772
http://dx.doi.org/10.3390/ijms242115789
_version_ 1785135353603031040
author Okon, Estera
Gaweł-Bęben, Katarzyna
Jarzab, Agata
Koch, Wojciech
Kukula-Koch, Wirginia
Wawruszak, Anna
author_facet Okon, Estera
Gaweł-Bęben, Katarzyna
Jarzab, Agata
Koch, Wojciech
Kukula-Koch, Wirginia
Wawruszak, Anna
author_sort Okon, Estera
collection PubMed
description Breast cancer (BC) is the most common malignancy among women worldwide. In recent years, significant progress has been made in BC therapy. However, serious side effects resulting from the use of standard chemotherapeutic drugs, as well as the phenomenon of multidrug resistance (MDR), limit the effectiveness of approved therapies. Advanced research in the BC area is necessary to create more effective and safer forms of therapy to improve the outlook for individuals diagnosed with this aggressive neoplasm. For decades, plants and natural products with anticancer properties have been successfully utilized in treating various medical conditions. Anthraquinone derivatives are tricyclic secondary metabolites of natural origin that have been identified in plants, lichens, and fungi. They represent a few botanical families, e.g., Rhamnaceae, Rubiaceae, Fabaceae, Polygonaceae, and others. The review comprehensively covers and analyzes the most recent advances in the anticancer activity of 1,8-dihydroanthraquinone derivatives (emodin, aloe-emodin, hypericin, chrysophanol, rhein, and physcion) applied both individually, or in combination with other chemotherapeutic agents, in in vitro and in vivo BC models. The application of nanoparticles for in vitro and in vivo evidence in the context of 1,8-dihydroanthraquinone derivatives was also described.
format Online
Article
Text
id pubmed-10648492
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106484922023-10-31 Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer Okon, Estera Gaweł-Bęben, Katarzyna Jarzab, Agata Koch, Wojciech Kukula-Koch, Wirginia Wawruszak, Anna Int J Mol Sci Review Breast cancer (BC) is the most common malignancy among women worldwide. In recent years, significant progress has been made in BC therapy. However, serious side effects resulting from the use of standard chemotherapeutic drugs, as well as the phenomenon of multidrug resistance (MDR), limit the effectiveness of approved therapies. Advanced research in the BC area is necessary to create more effective and safer forms of therapy to improve the outlook for individuals diagnosed with this aggressive neoplasm. For decades, plants and natural products with anticancer properties have been successfully utilized in treating various medical conditions. Anthraquinone derivatives are tricyclic secondary metabolites of natural origin that have been identified in plants, lichens, and fungi. They represent a few botanical families, e.g., Rhamnaceae, Rubiaceae, Fabaceae, Polygonaceae, and others. The review comprehensively covers and analyzes the most recent advances in the anticancer activity of 1,8-dihydroanthraquinone derivatives (emodin, aloe-emodin, hypericin, chrysophanol, rhein, and physcion) applied both individually, or in combination with other chemotherapeutic agents, in in vitro and in vivo BC models. The application of nanoparticles for in vitro and in vivo evidence in the context of 1,8-dihydroanthraquinone derivatives was also described. MDPI 2023-10-31 /pmc/articles/PMC10648492/ /pubmed/37958772 http://dx.doi.org/10.3390/ijms242115789 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Okon, Estera
Gaweł-Bęben, Katarzyna
Jarzab, Agata
Koch, Wojciech
Kukula-Koch, Wirginia
Wawruszak, Anna
Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer
title Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer
title_full Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer
title_fullStr Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer
title_full_unstemmed Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer
title_short Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer
title_sort therapeutic potential of 1,8-dihydroanthraquinone derivatives for breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648492/
https://www.ncbi.nlm.nih.gov/pubmed/37958772
http://dx.doi.org/10.3390/ijms242115789
work_keys_str_mv AT okonestera therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer
AT gawełbebenkatarzyna therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer
AT jarzabagata therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer
AT kochwojciech therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer
AT kukulakochwirginia therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer
AT wawruszakanna therapeuticpotentialof18dihydroanthraquinonederivativesforbreastcancer